These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

214 related items for PubMed ID: 31864393

  • 1. Chinese herbal medicine Tangshen Formula treatment for type 2 diabetic kidney disease in the early stage: study protocol for a randomized controlled trial.
    Jin D, Huang WJ, Meng X, Yang F, Bao Q, Zhang MZ, Yang YN, Ni Q, Lian FM, Tong XL.
    Trials; 2019 Dec 21; 20(1):756. PubMed ID: 31864393
    [Abstract] [Full Text] [Related]

  • 2. Chinese herbal medicine Tangshen Formula treatment of patients with type 2 diabetic kidney disease with macroalbuminuria: study protocol for a randomized controlled trial.
    Yan M, Wen Y, Yang L, Wu X, Lu X, Zhang B, Huang W, Li P.
    Trials; 2016 May 23; 17(1):259. PubMed ID: 27216240
    [Abstract] [Full Text] [Related]

  • 3. Effects of Tangshen Formula on urinary and plasma liver-type fatty acid binding protein levels in patients with type 2 diabetic kidney disease: post-hoc findings from a multi-center, randomized, double-blind, placebo-controlled trial investigating the efficacy and safety of Tangshen Formula in patients with type 2 diabetic kidney disease.
    Yang X, Zhang B, Lu X, Yan M, Wen Y, Zhao T, Li P.
    BMC Complement Altern Med; 2016 Jul 26; 16():246. PubMed ID: 27460780
    [Abstract] [Full Text] [Related]

  • 4. Efficacy and safety of tangshen formula on patients with type 2 diabetic kidney disease: a multicenter double-blinded randomized placebo-controlled trial.
    Li P, Chen Y, Liu J, Hong J, Deng Y, Yang F, Jin X, Gao J, Li J, Fang H, Liu G, Shi L, Du J, Li Y, Yan M, Wen Y, Yang W.
    PLoS One; 2015 Jul 26; 10(5):e0126027. PubMed ID: 25938778
    [Abstract] [Full Text] [Related]

  • 5. Effects of traditional Chinese herbal medicine in patients with diabetic kidney disease: study protocol for a randomized controlled trial.
    Wang M, Wang Z, Zhou J, Sun W, Wang Y, Han M, Yang H, Liu WJ, Wang Y.
    Trials; 2018 Jul 17; 19(1):389. PubMed ID: 30016983
    [Abstract] [Full Text] [Related]

  • 6. Chinese herbal medicine Shenzhuo Formula treatment in patients with macroalbuminuria secondary to diabetic kidney disease: study protocol for a randomized controlled trial.
    Zhao XM, Zhang Y, He XH, Chen HD, Wang ZF, Guo J, Wang XM, Gao ZZ, Wang JP, Liu W, Zhao LH, Tong XL.
    Trials; 2018 Mar 27; 19(1):200. PubMed ID: 29587863
    [Abstract] [Full Text] [Related]

  • 7. Effects of Keluoxin capsule combined with losartan potassium on diabetic kidney disease: study protocol for a randomized double-blind placebo-controlled multicenter clinical trial.
    Wu R, Wei F, Qu L, Bai L, Li J, Li F, Yan W, Wang Q, Wei J.
    Trials; 2020 Nov 23; 21(1):951. PubMed ID: 33228726
    [Abstract] [Full Text] [Related]

  • 8. A randomized controlled clinical trial study protocol of Liuwei Dihuang pills in the adjuvant treatment of diabetic kidney disease.
    Liao T, Zhao K, Huang Q, Tang S, Chen K, Xie C, Zhang C, Gan W.
    Medicine (Baltimore); 2020 Jul 31; 99(31):e21137. PubMed ID: 32756091
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of Shenyankangfu tablets for primary glomerulonephritis: study protocol for a randomized controlled trial.
    Kou J, Wu J, Yang HT, He YN, Fang JA, Deng YY, Xie YS, Nie LF, Lin HL, Cai GY, Chen XM.
    Trials; 2014 Dec 05; 15():479. PubMed ID: 25480673
    [Abstract] [Full Text] [Related]

  • 10. Prostaglandin E1 for preventing the progression of diabetic kidney disease.
    Wang H, Deng JL, Yue J, Li J, Hou YB.
    Cochrane Database Syst Rev; 2010 May 12; (5):CD006872. PubMed ID: 20464745
    [Abstract] [Full Text] [Related]

  • 11. Treatment effects of Chinese medicine (Yi-Qi-Qing-Jie herbal compound) combined with immunosuppression therapies in IgA nephropathy patients with high-risk of end-stage renal disease (TCM-WINE): study protocol for a randomized controlled trial.
    Li S, Li JP.
    Trials; 2020 Jan 06; 21(1):31. PubMed ID: 31907076
    [Abstract] [Full Text] [Related]

  • 12. The key role of Shenyan Kangfu tablets, a Chinese patent medicine for diabetic nephropathy: study protocol for a randomized, double-blind and placebo-controlled clinical trial.
    Wang H, Mu W, Zhai J, Xing D, Miao S, Wang J, Deng Y, Wang N, Chen H, Yang H, He X, Shang H.
    Trials; 2013 Jun 05; 14():165. PubMed ID: 23738508
    [Abstract] [Full Text] [Related]

  • 13. 'Huang Qi Elixir' for proteinuria in patients with diabetic nephropathy: a study protocol for a randomized controlled pilot trial.
    Tu X, Liu F, Jordan JB, Ye XF, Fu P, Wang F, Zhong S.
    Trials; 2013 Jul 18; 14():223. PubMed ID: 23866835
    [Abstract] [Full Text] [Related]

  • 14. Yinang formulation versus placebo granules as a treatment for chronic kidney disease stages III-IV in patients with autosomal dominant polycystic kidney disease: study protocol for a double-blind placebo-controlled randomized clinical trial.
    Gan J, Wu Y, Gong X, Ma Y, Yu S, Gao J.
    Trials; 2019 Aug 07; 20(1):481. PubMed ID: 31391092
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of Abelmoschus manihot for primary glomerular disease: a prospective, multicenter randomized controlled clinical trial.
    Zhang L, Li P, Xing CY, Zhao JY, He YN, Wang JQ, Wu XF, Liu ZS, Zhang AP, Lin HL, Ding XQ, Yin AP, Yuan FH, Fu P, Hao L, Miao LN, Xie RJ, Wang R, Zhou CH, Guan GJ, Hu Z, Lin S, Chang M, Zhang M, He LQ, Mei CL, Wang L, Chen X.
    Am J Kidney Dis; 2014 Jul 07; 64(1):57-65. PubMed ID: 24631042
    [Abstract] [Full Text] [Related]

  • 16. Abelmoschus manihot - a traditional Chinese medicine versus losartan potassium for treating IgA nephropathy: study protocol for a randomized controlled trial.
    Li P, Chen YZ, Lin HL, Ni ZH, Zhan YL, Wang R, Yang HT, Fang JA, Wang NS, Li WG, Sun XF, Chen XM.
    Trials; 2017 Apr 11; 18(1):170. PubMed ID: 28395659
    [Abstract] [Full Text] [Related]

  • 17. Semi-individualised Chinese medicine treatment as an adjuvant management for diabetic nephropathy: a pilot add-on, randomised, controlled, multicentre, open-label pragmatic clinical trial.
    Chan KW, Ip TP, Kwong AS, Lui SL, Chan GC, Cowling BJ, Yiu WH, Wong DW, Liu Y, Feng Y, Tan KC, Chan LY, Leung JC, Lai KN, Tang SC.
    BMJ Open; 2016 Aug 05; 6(8):e010741. PubMed ID: 27496229
    [Abstract] [Full Text] [Related]

  • 18. Rationale, design, and baseline characteristics of the CArdiovascular safety and Renal Microvascular outcomE study with LINAgliptin (CARMELINA®): a randomized, double-blind, placebo-controlled clinical trial in patients with type 2 diabetes and high cardio-renal risk.
    Rosenstock J, Perkovic V, Alexander JH, Cooper ME, Marx N, Pencina MJ, Toto RD, Wanner C, Zinman B, Baanstra D, Pfarr E, Mattheus M, Broedl UC, Woerle HJ, George JT, von Eynatten M, McGuire DK, CARMELINA® investigators.
    Cardiovasc Diabetol; 2018 Mar 14; 17(1):39. PubMed ID: 29540217
    [Abstract] [Full Text] [Related]

  • 19. [Treatment of stage 3b diabetic kidney disease patients with macroalbuminuria by qizhi jiangtang capsule: a multicenter randomized control clinical study].
    Guo ZA, Yu CJ, Liu G, Meng FC, Li Y, Peng SL.
    Zhongguo Zhong Xi Yi Jie He Za Zhi; 2014 Sep 14; 34(9):1047-52. PubMed ID: 25335326
    [Abstract] [Full Text] [Related]

  • 20. Chinese herbal medicine for diabetic kidney disease: a systematic review and meta-analysis of randomised placebo-controlled trials.
    Zhang L, Yang L, Shergis J, Zhang L, Zhang AL, Guo X, Qin X, Johnson D, Liu X, Lu C, Xue CC, Mao W.
    BMJ Open; 2019 May 01; 9(4):e025653. PubMed ID: 31048437
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.